| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...626143W |
| P356 | DOI | 10.1371/JOURNAL.PONE.0026143 |
| P8608 | Fatcat ID | release_wvgjca3lmfaofiffnognibpjry |
| P932 | PMC publication ID | 3191176 |
| P698 | PubMed publication ID | 22022540 |
| P5875 | ResearchGate publication ID | 51737872 |
| P50 | author | Jinhai Huang | Q61139401 |
| Robert P. Kimberly | Q41183568 | ||
| P2093 | author name string | Jeffrey C Edberg | |
| Xiulong Xu | |||
| Jianming Wu | |||
| Fenglong Xie | |||
| Andrew W Gibson | |||
| Lena Al-Harthi | |||
| Maureen H Richards | |||
| Rui Lin | |||
| P2860 | cites work | The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors | Q22003989 |
| Identification of c-MYC as a target of the APC pathway | Q24310637 | ||
| Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma | Q24336272 | ||
| Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC | Q24336321 | ||
| Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box | Q24561560 | ||
| CD95 promotes tumour growth | Q24602589 | ||
| Structural basis for DNA bending by the architectural transcription factor LEF-1 | Q27729834 | ||
| A New Statistical Method for Haplotype Reconstruction from Population Data | Q27860495 | ||
| Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease | Q28115268 | ||
| Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation | Q28248826 | ||
| LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected] | Q28268708 | ||
| A thymus-specific member of the HMG protein family regulates the human T cell receptor C alpha enhancer | Q28271385 | ||
| Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand | Q28513283 | ||
| Deletion of β-catenin impairs T cell development | Q28587501 | ||
| A comparison of bayesian methods for haplotype reconstruction from population genotype data | Q29547566 | ||
| The Fas death factor | Q29620461 | ||
| Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis | Q30080034 | ||
| Features associated with, and the impact of, hemolytic anemia in patients with systemic lupus erythematosus: LX, results from a multiethnic cohort | Q33380972 | ||
| The Fas counterattack: cancer as a site of immune privilege | Q33542332 | ||
| Stabilisation of β-Catenin Downstream of T Cell Receptor Signalling | Q33700471 | ||
| Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway | Q33766466 | ||
| The Yin-Yang of TCF/beta-catenin signaling | Q33767101 | ||
| Cyclosporin A-sensitive transcription factor Egr-3 regulates Fas ligand expression | Q33774541 | ||
| Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin | Q33775965 | ||
| TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling | Q34122210 | ||
| Fas ligand expression is a risk factor for liver metastasis in colorectal cancer with venous invasion. | Q51021146 | ||
| Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations | Q57078480 | ||
| A role for CD95 ligand in preventing graft rejection | Q59066471 | ||
| Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer | Q59881664 | ||
| Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege | Q63408406 | ||
| The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice | Q71678868 | ||
| Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape | Q71762882 | ||
| Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? | Q71840957 | ||
| Novel Egr/NF-AT composite sites mediate activation of the CD95 (APO-1/Fas) ligand promoter in response to T cell stimulation | Q73046111 | ||
| Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells | Q73935008 | ||
| The beta-catenin--TCF-1 pathway ensures CD4(+)CD8(+) thymocyte survival | Q74286666 | ||
| A regulatory element in the CD95 (APO-1/Fas) ligand promoter is essential for responsiveness to TCR-mediated activation | Q77115244 | ||
| Expression of CD95 ligand in melanocytic lesions as a diagnostic marker | Q77393465 | ||
| Viral IFN-regulatory factors inhibit activation-induced cell death via two positive regulatory IFN-regulatory factor 1-dependent domains in the CD95 ligand promoter | Q77522390 | ||
| Induction of specific T cell tolerance by Fas ligand-expressing antigen-presenting cells | Q78109619 | ||
| TCF-1, a T cell-specific transcription factor of the HMG box family, interacts with sequence motifs in the TCR beta and TCR delta enhancers | Q95815011 | ||
| Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. | Q34461429 | ||
| Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo | Q34486226 | ||
| Vitamin E inhibits CD95 ligand expression and protects T cells from activation-induced cell death | Q34795697 | ||
| Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege | Q35045303 | ||
| Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer | Q35354010 | ||
| Fas ligand upregulation is an early event in colonic carcinogenesis | Q35399449 | ||
| The Fas signalling pathway and its role in the pathogenesis of cancer | Q35834880 | ||
| The central role of Fas-ligand cell signaling in inflammatory lung diseases. | Q35921529 | ||
| Expression of Fas ligand in liver metastases of human colonic adenocarcinomas | Q36186304 | ||
| Identification of a core motif that is recognized by three members of the HMG class of transcriptional regulators: IRE-ABP, SRY, and TCF-1 alpha | Q36270299 | ||
| The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand | Q36367323 | ||
| Fas ligand triggers pulmonary silicosis | Q36369388 | ||
| FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. | Q36403535 | ||
| Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. | Q36671108 | ||
| Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? | Q37364901 | ||
| Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes | Q37383034 | ||
| Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. | Q37391035 | ||
| FASLG polymorphism is associated with cancer risk | Q37464413 | ||
| Human lung carcinomas express Fas ligand. | Q41120854 | ||
| B cells in systemic autoimmune disease: recent insights from Fas-deficient mice and men. | Q41312443 | ||
| TCF/LEF factor earn their wings | Q41684115 | ||
| Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory res | Q42020354 | ||
| A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients | Q42434981 | ||
| Transcriptional regulation of the human FasL promoter-enhancer region | Q42450959 | ||
| The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures | Q42459873 | ||
| Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. | Q42830166 | ||
| Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis | Q44455328 | ||
| Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene | Q46906570 | ||
| Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. | Q46925453 | ||
| Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma | Q47230945 | ||
| A newly identified response element in the CD95 ligand promoter contributes to optimal inducibility in activated T lymphocytes | Q47757477 | ||
| The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. | Q48032094 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e26143 | |
| P577 | publication date | 2011-10-11 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Human FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions | |
| P478 | volume | 6 |
| Q87098038 | Association of genetic variants in apoptosis genes FAS and FASL with radiation-induced late toxicity after prostate cancer radiotherapy |
| Q42286900 | Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner |
| Q86882836 | LRP5 and plasma cholesterol levels modulate the canonical Wnt pathway in peripheral blood leukocytes |
| Q89248716 | T-cell factor (TCF/LEF1) binding elements (TBEs) of FasL (Fas ligand or CD95 ligand) bind and cluster Fas (CD95) and form complexes with the TCF-4 and b-catenin transcription factors in vitro and in vivo which result in triggering cell death and/or |
| Q36739216 | The Wnt/β-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer |
| Q43622589 | VEGFA rSNPs, transcriptional factor binding sites and human disease |
Search more.